02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
21:34 , May 8, 2019 |  BC Extra  |  Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
17:40 , Mar 28, 2019 |  BC Extra  |  Financial News

CanSino shares rise in first day of Hong Kong trading

CanSino rose HK$12.70 (58%) to HK$34.70 in its first day of trading Thursday after raising HK$1.3 billion (US$160.5 million) in its IPO. The performance may signal renewed confidence in China’s domestic vaccine companies. CanSino Biologics...
00:38 , Mar 27, 2019 |  BC Extra  |  Financial News

CanSino raises $161M in Hong Kong IPO

CanSino will begin trading Thursday after raising HK$1.3 billion (US$160.5 million) early Wednesday with an IPO that valued the vaccine company at HK$4.8 billion (US$611.6 million). CanSino Biologics Inc. (HKSE:6185) sold 57.2 million shares at...
16:57 , Mar 22, 2019 |  BC Week In Review  |  Financial News

CanSino could get $598M valuation in Hong Kong IPO

By Hongjiang Li, Staff Writer CanSino would be valued at HK$4.7 billion (US$597.6 million) if the prerevenue vaccine company prices its Hong Kong IPO at the midpoint of the range it proposed Monday. CanSino Biologics...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
23:03 , Nov 2, 2018 |  BioCentury  |  Finance

Innovent’s Hong Kong spark

A strong performance out of the gate for Innovent Biologics Inc. (HKSE:1801) reflects investor confidence in the company’s pipeline regardless of market conditions. The biologics company raised HK$3.3 billion ($421 million) in an IPO priced...
03:06 , Aug 8, 2018 |  BC Extra  |  Financial News

BeiGene dips slightly in Hong Kong debut

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) slipped HK$1 to HK$107 in its first day of trading on the Hong Kong exchange Wednesday. Last week, the company raised HK$7.1 billion ($902.7 million) by pricing its Hong Kong listing...